Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 3/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066035 | 1.00 | NPY5R (0.44) | NPY5RPDK2RAB9ANQO2HPGDS | |
| SCHEMBL19065269 | 0.92 | PDK2 (0.46) | NPY5RPDK2HPGDSSCN2ACOMT | |
| SCHEMBL19065720 | 0.90 | NPY5R (0.45) | NPY5RPDK2RAB9ANQO2HPGDS | |
| SCHEMBL19065430 | 0.88 | PDK2 (0.42) | NPY5RPDK2HPGDSSCN2ACYP4F2 | |
| Trifluoroacetic Acid SCHEMBL29676048 | 0.87 | PDK2 (0.49) | NPY5RPDK2SCN2ADGAT1 | |
| Trifluoroacetic Acid SCHEMBL19065513 | 0.87 | PDK2 (0.49) | NPY5RPDK2SCN2ADGAT1 | |
| SCHEMBL19065377 | 0.86 | ALDH1A1 (0.41) | NPY5RPDK2CYP4F2CYP4A11MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL29675566 | 0.85 | NPY5R (0.41) | NPY5RPDK2RAB9ANQO2SCN2A | |
| Trifluoroacetic Acid SCHEMBL19065548 | 0.85 | NPY5R (0.41) | NPY5RPDK2RAB9ANQO2SCN2A | |
| SCHEMBL19066083 | 0.85 | NPY5R (0.48) | NPY5RHPGDSSCN2AMAP4K4TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885PDK2 163/4885RAB9A 895/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885PDK2 163/4885RAB9A 895/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885PDK2 163/4885RAB9A 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.